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vAbstract
We present a morphometry method which uses brain models generated using Nonnegative
Matrix Factorization (NMF) characterized by signatures calculated from perceptual features
such as intensities, edges and orientations, of some regions obtained by comparing the mod-
els. Two different measures are used to calculate volume-models distances in the regions of
interest. The discerning power of these distances is tested by using them as features for a
Support Vector Machine classifier.
This work shows the usefulness of both measures as metrics in medical image applications
when they are used in binary classification tasks. Our methodology was tested with two
experimental groups extracted from a public brain MR dataset (OASIS), the classification
between healthy subjects and patients with mild AD reveals an equal error rate (EER) mea-
sure which is better than previous approaches tested on the same dataset (0.1 in the former
and 0.2 in the latter). When detecting very mild AD, our results (near to 75% of sensitivity
and specificity) are comparable to the results with those approaches.
Keywords: Alzheimer’s Disease, MRI, Morphometry, NMF, Pattern Recognition, Kullback-
Leibler Divergence, Earth Mover’s Distance.
Resumen
Presentamos un me´todo de morfometr´ı que usa modelos de cerebro que se generan usando
factorizacio´n de matrices no-negativas (NMF por su nombre en ingle´s) y se caracterizan
por firmas calculadas de rasgos perceptules como las intensidades, bordes y orientaciones de
algunas regiones del cerebro obtenidas de la comparacio´n entre modelos. Dos medidas, la
divergencia de Kullback-Leibler y la “Earth Mover’s Distance”, son usadas para calcular la
distancia entre volu´menes y modelos en las regiones de intere´s. Probamos el poder discrim-
inante de estas distancias usa´ndolas para construir los vectores de caracter´ısticas para una
ma´quina de soporte vectorial.
Este trabajo muestra la utilidad de ambas medidas en tareas de clasificacio´n binaria. Nues-
tra metodolog´ıa fue probada con dos grupos experimentales extra´ıdos de la base de datos
OASIS, la clasificacio´n entre sujetos sanos y pacientes con Alzheimer leve revela un EER que
mejora los resultados obtenidos por trabajos publicados previamente con los mismos grupos
experimentales. Cuando se trata de detectar Alzheimer muy leve, los resultados (cercanos a
75% de sensibilidad y especificidad) son comparables con los resultados obtenidos en dichas
publicaciones.
Palabras Clave: Enfermedad de Alzheimer, IRM, Morfometr´ıa, NMF, Reconocimiento de
Patrones, Divergencia de Kullback-Leibler, EMD.
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1 Introduction
1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative diseas that affects higher brain functions
like memory, thinking and behavior. The neuropathological changes asociated with AD in-
clude intraneuronal lesions (neurofibrillary tangles) and extracellular parenchymal lesions
(senile plaques), these changes are often acompanied by synaptic loss and vascular amyloid
deposits [1, 2].
Although the disease progression has been traditionally assessed under the Braak and Braak
staging scheme [3], several reports [4, 5, 6, 7] have demonstrated a very variable AD clinical
picture: Neither the progression patterns nor the same anatomical areas are involved or
follow a reproducible anatomic sequence, even in series of patients belonging to comparable
social and cultural environments. Approximately 25% of AD brains show atypical patterns
of structural damage, usually classified as hippocampal sparing and limbic predominant AD
[8]. Furthermore, AD can also manifest different clinical pictures, such as the posterior,
logopenic and frontal variants (IGW-2).
There are a few drugs that temporarily improve the symptoms of Alzheimers disease by
increasing the amount of neurotransmitters in the brain. However, no treatment is available
to slow or stop the deterioration of brain cells in Alzheimer’s disease, but researches around
the world are studying numerous treatment strategies that may have the potential to change
the course of the disease, approximately 75 to 100 experimental therapies aimed at slowing
or stopping the progression of Alzheimer’s are in clinical testing in human volunteers [9].
Excluding the rare cases of AD caused by genetic mutations (less than 1% of cases), experts
believe that Alzheimer’s develops as result of multiple factors rather than a single cause. The
greatest risk factor for AD is age, but the disease is not a normal part of the ageing process,
other known risk factors for AD are: family history, APOE − 4 gene, Mild Cognitive Im-
pairment (MCI), cardiovascular diseases, traumatic brain injury and cognitive engagement
[10].
The AD is the most common type of dementia and the fifth leading death cause of people
over 65 years [11], the increased life expectancy and aging of the general population have
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made of Alzheimer’s Disease (AD) a growing public health concern. In 2013, over 35 million
people worldwide were living with the disease, this number is expected to double by 2030
and more than triple by 2050 to 115 million [12]. Other reports calculate that by the year
2050 there will be approximately 135 million patients suffering from different stages of AD
[13].
As the global population ages, the number of deaths related to Alzheimer’s disease are grow-
ing in almost every country [14]. As example, between 2000 and 2013, deaths attributed to
Alzheimer’s disease increased 71 percent in United States [10]. Figure 1-1 shows the increas-
ing number of deaths related to AD and other dementias in Colombia between 1998 and 2012.
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Figure 1-1: Number of deaths realted to AD and other dementias of people over 60 years.
This data was taken from the death records of DANE (Departamento Adminis-
trativo Nacional de Estadistica).
It is important to note that even in countries with complete medical certification of causes
of death, the number of deaths due to AD and other dementias has been systematically
underestimated because the lack of accurate diagnosis and theses deaths were associated to
broad causes such as senility.
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1.2 Diagnosis of AD
The clinical diagnosis of probable AD has been based on the criteria established in 1984 by
the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimers
Disease and Related Disorders Association (NINCDS-ADRDA) [15] and the criteria from
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [16], these criteria
specify eight cognitive domains that may be impaired in AD: memory, language, perceptual
skills, attention, constructive abilities, orientation, problem solving and functional abilities.
In 2010 the National Institute on Aging and the Alzheimers Association proposed recom-
mendations to update the diagnostic criteria for Alzheimers dementia and MCI [17]. All of
the recommendations incorporate the use of biomarkers for diagnosis, Among the biomark-
ers being considered are brain volume, level of glucose metabolism in the brain, presence of
beta-amyloid in the brain and levels of beta-amyloid and tau in cerebrospinal fluid.
All the clinical criteria proposed allow diagnosis of probable disease, a definitive diagnosis of
AD can only be made via histopathological confirmation of amyloid plaques and neurofibril-
lary tangles but these confirmations studies are usually performed post mortem. Although
precise guidelines for AD diagnosis exist [18] the final responsibility of deciding whether the
patient is suffering from AD or not falls upon the physician.
AD is commonly detected when a physician is consulted due to cognitive impairment or
memory complaints. The initial diagnosis is based on the patient’s clinical history and a
battery of neuropsychological tests measuring different disease aspects such as symptom
severity, interference with the patient activities, or cognitive impairment, among others.
Certain routine laboratory test and routine brain imaging are also recommended, but these
are to rule out other conditions that can cause cognitive dysfunction. The accuracy of the
diagnosis is highly dependent on the examiner’s skills and on the evolution of a variable
clinical frame. Studies report that only 50% of the cases of probable dementia are correctly
diagnosed [19].
1.2.1 Neuropsychological Tests
The neuropsychological tests used in the AD diagnosis process include the following:
• The Clinical Dementia Rating (CDR) is used to quantify the severity of symptoms
of dementia. The test consists on a semi-structured interview with an informant and
the patient to measure the cognitive and functional performance in six areas: memory,
orientation, judgment and problem solving, community affairs, home and hobbies, and
finally, personal care. In the scoring rules memory is considered the primary category
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and all others are secondary. The current version of this test was published by Morris
in 1993 [20].
• The MiniMental State Examination (MMSE) or Folstein Test is used to estimate the
severity of cognitive impairment evaluating the following aspects: orientation to time
and place, registration, attention and calculation, recall, language, repetition and com-
plex commands. This test was published in 1975 by Folstein et al. [21].
• The Alzheimers Disease Assessment Scale - Cognition (ADAS-Cog) is used to evaluate
cognitive impairment in the assessment of Alzheimers disease, its primary purpose was
to be an index of global cognition in response to antidementia therapies. This scale
was proposed by Rosen et al. in 1984 [22].
1.2.2 Early Diagnosis
The brain changes underlying Alzheimer’s disease probably develop over a period of at least
10-20 years prior to the onset of symptoms [23], and researches believe that this may be the
period where future Alzheimer drugs and treatments will be most effective.
The primary purpose of early diagnosis is timely access to information, advice and support
for the patients, their relatives and caregivers. Other important benefits of early detection
and diagnosis are [9]:
• Prompt evaluation and treatment of reversible or treatable causes of cognitive impair-
ment.
• Enables potential inclusion in Alzheimer clinical trials.
• Helps prevent prescription of medications for coexisting conditions that worsen cogni-
tive function.
• Aids management of possible behavioral symptoms.
• Allows planning for the future.
The increasing burden of the disease due to population growing and ageing is becoming a
worldwide public health concern, researchers around the world are working in the develop-
ment of medical treatments that should be given when extensive and irremediable damage
has not occurred yet, this is the period when brain changes are beginning but major symp-
toms as memory loss have not appear.
Given that the first AD symptoms may be confused with other conditions, there is a strong
interest in developing objective tools that allow the early clinical detection and the recogni-
tion of the prodromal expression of AD, making this a burgeoning area of research.
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1.3 Medical Imaging in AD
Due to their noninvasive and harmless nature, neuroimages constitute a potential source of
information, but as mentioned before, their utility remains limited.
The prospect of using neuroimaging techniques as both an early detection and a confirmation
tool is very appealing and has generated a large body of research. In the clinical practice,
however, neuroimaging techniques have had, until now, only a marginal role: Their main use
is to exclude other pathological conditions or to visualize the anatomic pattern of neurode-
generation. Recent reviews on the NINCDS-ADRDA Alzheimer’s Criteria [18] recommend
using MR neuroimages as a supportive diagnosis tool while the IWG-2 criteria suggest the
use of amyloidPET as evidence of Alzheimer’s pathology. Volumetry of the hippocampus
and the medial temporal lobe (MTL) has gained wide acceptance as a diagnostic tool and
biomarker of the disease progression, yet the disease management is independent of these
measures. It should be noted that the presence of atypical AD pathology and other diseases,
such as the hippocampal sclerosis, compromise the reliability of the data obtained with this
technique.
Structural Magnetic Resonance Imagin (MRI) provide precise anatomical information but
are rarely used to detect AD as the anatomical changes it induces tend to be slow, subtle
and hard to differentiate from normal brain aging. Despite this, recent articles have used
morphometry based approaches to identify the anatomical differences between groups of
healthy and AD patients [24, 25, 26].
1.4 State-of-the-Art
1.4.1 Brain Morphometry
Several studies report the use of sophisticated measurement techniques that assess anatom-
ical changes in areas compromised by AD such as the intracranial volume, the cortical
thickness or volumes of subcortical structures [27]. The computational methods that per-
form these measurements are collectively known as Brain Morphometry (BM) or, in some
cases, computational neuroanatomy or neuromorphometry [28]. As the names suggest, these
methods are only based on form, size and/or shape derived features extracted from the brain
structures.
Features such as locations (landmarks), voxel intensities, template deformations or surface
representations have been frequently used in morphometrical studies, giving place to specific
morphometric techniques such as landmark-based morphometry [29], voxel-based morphom-
etry [30], deformation-based or tensor-based morphometry [31] and surface-based morphom-
etry [32].
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Voxel-Based Morphometry (VBM), proposed by Ashburner and Friston in 2000 [30], is by
far the most common morphometric approach used by the neuroscience research community.
Based on brain tissue segmentation and voxel-by-voxel global statistics, VBM is driven by
the mesoscopic differences, i.e. local differences, between subject volumes and the entire
population. By contrast, Deformation-Based Morphometry (DBM), proposed in 1998 by
Ashburner et al. [31] models macroscopic anatomical differences among brains using the de-
formation fields that warp individual brains to a common reference space. The deformation
fields are expected to encode shapes of individual brains, providing additional information
to the shape analysis about lengths, areas and angles, among others.
A drawback of morphometrical analyses is the need of an accurate intersubject registration
that guarantees the comparison of homologous structures across all subjects. However, this
kind of one-to-one correspondence between subjects may not always be achieved, mainly be-
cause of the inherent intersubject anatomical variability and the effects of brain pathologies.
To cope with this, Toews et al. [33] proposed in 2010 Feature-Based Morphometry (FBM)
devised to find image patterns that might not occur in all subjects. Since each subject is
modeled as a collection of brain features, a probabilistic framework estimates the relation-
ship between features and subjects, thereby clustering the co-ocurrence between features and
classes.
It has to be noted that several these morphometry methods used to detect AD are based or
rely on segmentation techniques: Some studies use automatic segmentation of main tissues
such as cerebrospinal fluid, gray and white matter [26, 34, 35, 36, 37], other studies use semi-
automatic segmentation of specific areas such as the hippocampus [38], or combinations of
them [39, 40, 19, 41, 42].
1.4.2 Pattern Recognition Techniques
The use of machine learning and elaborate data interpretation techniques has become com-
mon for the analysis of neurological images due to their high dimensionality and complexity.
These approaches combine different sets of features obtained from neurological volumes as
input to supervised classification algorithms that learn how to assign predefined labels, e.g.
AD or NC, to previously unseen volumes [26]. Part of the appeal of these methods comes
from their increased discriminating power due to the combination weighted sets of features
instead of having to rely on a single one. Machine learning in this context works by learning
a set of bases from the feature space in which the brains are encoded and finding relevant
relationships among them. The choice of these bases is dependent on an output variable
describing a particular condition to be explained, e.g. the presence or absence of particular
pattern in neurodegenerative disorders, or the identity of a recorded stimulus or task.
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A common approach in the analysis of neuroimages is reduced to a classification problem,
that is, the objective of the methods is to extract features from the images that can be used
to assign labels related to clinical conditions, i.e. AD/nonAD or MCI/AD. Typical examples
of this approach are Support Vector Machines (SVM) and ensemble classifiers. The former
are binary classifiers broadly used in different artificial vision problems. SVM assume that
there is a feature space in which the two classes are separable by a hyperplane. The use of
SVM in neuroimaging research has been reported in various publications[24, 43].
1.5 Proposed Approach
In the present work we propose a methodology that extracts characteristic morphological in-
formation of groups of Magnetic Resonance Images (MRI) from diverse information channels
(e.g. intensities, edges and orientations) and then condenses this information into charac-
teristic brain models.
We use Non-negative Matrix Factorization (NMF) to obtain brain volumes representing
different stages of the disease, a comparison between these models gives us the most dis-
criminant regions between classes for each information channel. Note that these regions are
important not only because of their use as classification features but, more significantly,
because they blend intuitively with the doctors’ diagnostic thought process.
To validate our models, we calculate a signature for each one of the discriminant regions
in the MRIs and the models and compare these regions in the MRIs against the regions in
the brain models by using two similarity measures: the Kullback-Leibler divergence and the
Earth Mover’s Distance.
With the obtained measures, we train a SVM classifier where each feature vector was com-
posed by all the similarity measures between the corresponding MRI and both brain volumes.
In this work we present an automatic methodology to learn a brain model for each stage
of the disease and obtain discerning regions from them. With the regions and the models
we obtain useful classification features that allow high sensitivity and specificity with lower
dimensionality in the detection of AD.
2 Methods and Materials
2.1 Methods
The overall methodology is presented schematically in Figure 2-1. The generation of the
model volumes for each class is done using Nonnegative Matrix Factorization (NMF), RoI
extraction is based on the thresholding of the difference between the model volumes, and
two similarity measures are used to compare the signatures of corresponding regions.
NMF Models
Generation
Stage A Stage B
Regions of
Interest
Labeled Volumes
Similarity Measure
Masked Volumes
Stage A Stage B
Histograms per RoI
Stage A Stage B
Fe
atu
re 
Ca
lcu
lat
ion
SVM
 Training Classi�er
Test Data
Feature
Calculation
SAB
Figure 2-1: Graphical flow representation of the proposed method.
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2.1.1 Generation of Models
NMF is a dimensionality reduction technique which may be used to learn the most repre-
sentative “parts” that compose the elements of a set, e.g. NMF has been used to learn
individual parts of the face from a database and then use them to reconstruct and identify
any individual face [44].
Given a matrix X, where each column is a d-dimensional vector of positive observations for
each one of the N subjects, the NMF algorithm factorizes the matrix X into two non-negative
matrices W and H:
Xd×N = Wd×rHr×N (2-1)
with the following constraints:
wik ≥ 0 and hkj ≥ 0, ∀i, k, j (2-2a)
d∑
i=1
wik = 1, ∀k ∈ {1, . . . , r} (2-2b)
Where r is the rank of the decomposition corresponding to the number of columns in W and
the number of rows in H. The columns of W are called the basis vectors and the columns
of H are the projections of the data into the sub-space spanned from W .
Each column in X corresponds to a brain volume Ij and H is fixed using class membership
functions for each volume. Matrix W is found by solving the optimization problem of
minimizing the Kullback-Leibler divergence (KL) between X and WH as in [44]. The rank
of the decomposition r is the number of classes used in H, and it will be the number of
columns in the obtained matrix W which are the brain models for the corresponding classes.
This data arrangement is illustrated in Figure 2-2
2.1.2 Obtaining Models by Fusing with Clinical Data
In the present application have been used three stages as classes: Normal Control sub-
jects (NC), patients with very mild Alzheimer’s disease (or Mild Cognitive Impairment) and
patients with mild Alzheimer’s disease (mAD). The matrix H is fixed using membership
functions for each class that takes into account the neuropsychological information, in this
work we have used the Clinical Dementia Rating to establish the membership of each subject
to each class and posed binary functions as follows:
Hjk = fj(Ik) =
{
1 Ik ∈ Class j
0 otherwise
(2-3)
With these values, the resulting matrix W is composed by the basis vectors VmAD, VMCI
and VNC which, in this case, tend towards the average of the class members.
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Figure 2-2: Data arrangement for the NMF decomposition.
2.1.3 Regions Of Interest
A difference volume DAB = |VA − VB| is calculated to locate the regions with the most
discriminant information between class A and class B. Then, a set of regions of interest is
extracted from the difference volume DAB by applying two thresholds: the first one binarizes
DAB and the second one is a size filter that removes very small areas that are not represen-
tative. The process is repeated for each information channel f , as result we obtain a set of
RoI for each pair of classes and morphological information channel SfAB = {S1AB, . . . , SRfAB},
Figure 2-3 illustrates how this process works with different morphological information.
The set SfAB is used to mask the brain volumes {Ifj }nj=1 and the model volumes {V fA , V fB}.
Then, each of the regions is represented by a signature, in this case, a 256 or 64 bin histogram.
2.1.4 RoI Comparison
The histogram hfj,r summarizes the information of the subject j in the region S
r
AB, that
belongs to the set SfAB, for the channel f . In a similar way, the histograms {hfA,r, hfB,r}
represent the information of the model volumes in the region SrAB for the channel f . Then,
the region in the subject j is compared to the regions in the models using a similarity
measure between the histograms, in this work we have used two measures: the Kullback-
Leibler divergence (KL-div) and the Earth Mover’s Distance (EMD).
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Figure 2-3: An example of how the set of Regions of Interest (RoI) is obtained for some
morphological information channel.
KL Divergence
The Kullback-Leibler divergence, also known as the relative entropy, is a widely used mea-
sure of the difference between probability density functions. Given two discrete probability
distributions p and q, the KL divergence between p and q is a measure of the information
lost when q is used to approximate p and is defined by:
DKL(p‖q) =
∑
m
pm ln
pm
qm
(2-4)
Although DKL(p‖q) 6= DKL(q‖p), so this measure is not symmetric and cannot be a true
metric, it satisfies two important properties:
DKL(p‖q) ≥ 0 ∀p, q (2-5a)
DKL(p‖q) = 0 if and only if p = q (2-5b)
Note that this measure has problems when there are zero values in the probability distribu-
tions, to prevent this issue we have replaced the zeros in the histograms with a very small
value just before the histogram normalization.
Then, for the subject j, the region SrAB and the channel f , we calculate the following pair(
DKL(hˆ
f
j,r‖hˆfA,r), DKL(hˆfj,r‖hˆfB,r)
)
(2-6)
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Where hˆfj,r, hˆ
f
A,r and hˆ
f
B,r are the corresponding normalized histograms. This pair of numbers
are measures of the amount of information lost when the regions in the models are used to
represent the regions in the subjects.
Earth Mover’s Distance
EMD is a similarity measure that calculates the minimum cost of transforming one histogram
into another [45]. Finding the EMD is equivalent to solving an instance of the transportation
measurement problem[46] in which n suppliers with fixed offers S = {s1, s2, . . . , sn} have to
cover the demands C = {c1, c2, . . . , cm} of m consumers to which they are connected through
paths with a positive given cost {pij}n,mi,j=1. The solution satisfies the consumers’ demand while
minimizing the transportation costs. The general transportation problem is illustrated in
Figure 2-4.
. . .
. . .
n suppliers
With �xed oﬀers
m consumers
With �xed demands
nxm paths
With given costs
Figure 2-4: Graphical explanation of the Transportation Problem.
This problem can be written in terms of the amount of “earth” xij that is moved from
supplier i to consumer j:
minimize
X
n∑
i=1
m∑
j=1
pijxij (2-7)
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subject to
m∑
j=1
xij ≤ si, for i ∈ {1, . . . , n} (2-8a)
n∑
i=1
xij ≥ cj, for j ∈ {1, . . . ,m} (2-8b)
xij ≥ 0, for i ∈ {1, . . . , n} and j ∈ {1, . . . ,m} (2-8c)
If the solution of this problem is the set of values {x∗ij}n,mi,j=1, one can say that the earth
mover’s distance between S and C is the total cost divided by the amount of mass that is
moved:
EMD(S, C) = 1∑
ij x
∗
ij
(
n∑
i=1
m∑
j=1
pijx
∗
ij
)
(2-9)
When comparing two histograms or signatures (a generalized form of histograms) these can
be seen as the sets of offers and demands, if the histograms have the same mass, as in our
case, the problem is symmetric and the EMD is a metric equivalent to the Wasserstein’s
distance [45]. Figure 2-5 shows a simple example of EMD between two histograms p and q.
Figure 2-5: In this case the EMD between p and q is the cost of moving one unit from one
bin to the next divided by the total mass: 1/3.
As with the KL-div, for each subject, region and channel we calculated the following pair:(
EMD(hfj,r, h
f
A,r), EMD(h
f
j,r, h
f
B,r)
)
(2-10)
For each subject, all pairs of measures along all the regions and channels are concatenated
to make up a feature vector for the classification task. The length of these vectors are
dependent on the number of RoI obtained for each channel and is given by the expression∑
f 2Rf
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2.2 Materials
2.2.1 MRI Data
In this work we have used T1 weighted magnetic resonance images of the brain, the images
come from the Open Access Series of Imaging Studies (OASIS) database [47], the images in
this study were aquired with 1.5 T Vision scanner.
Pre-processing
As described in [47] the postprocessing includes: removal of facial features, correction for
head movement, location of all volumes in the same coordinate system, affine registration to
the Talairach and Tournoux atlas [48], skull removal and intensity inhomogeneity correction.
All these steps were already for the images in the OASIS database.
We have registered the brain volumes to the MNI152 space using the affine registration tool
FLIRT [49, 50] in the FSL library (http://fsl.fmrib.ox.ac.uk/fsl/), This procedure
was done with the purpose of being able to identify anatomical regions using the structural
atlases provided by the FSL library.
The result of this process is a single 1-mm isotropic volume with 176× 208× 176 voxels.
2.2.2 Clinical Data
Dementia status of the subjects in OASIS was established and staged using the CDR scale,
this scale allows the clinical diagnosis of probable Alzheimer’s Disease in subjects with a
CDR of 0.5 or greater.
We tested the region extracting method with a subset of the available data composed by
individuals aged from 60 to 80 with a CDR not greater than 1. The distribution by gender
and stage of the disease of this group is shown in Table 2-1.
Table 2-1: Distribution of the individuals in our experimental group.
CDR Stage Women Men Total
1 mild AD 13 7 20
0.5 very mild AD 28 22 50
0 NC 48 18 66
All 89 47 136
The MMSE scores for all the subjects in our experimental group are also available as a
supporting measure.
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2.2.3 Morphological Information Extraction
For each volume, the edge channel was obtained by applying a 3D Sobel filter over the whole
volume. The orientation channel was obtained by applying a 2D Gabor filters per slice in
the sagittal axis.
2.3 Evaluation
To test the discriminant nature of the obtained regions and the usefulness of the chosen
similarity measures, we have used the inter-region measures to build features to train a
Support Vector Machine classifier (SVM). The training features for each subject are the
measures calculated in 2.1.4, these features are concatenated and then they are used to train
an SVM binary classifier using the libSVM library [51].
The validation was performed using a leave-one-out cross-validation. In this scheme, a
single MRI is classified using the classifier trained with the remaining observations. The
calculation of the feature vector for the test subject is based on the model volumes and sets
of RoI obtained from the training data. Note that each iteration requires re-calculating a
new set of model volumes and RoI to effectively isolate the test subject.
The validation of the whole methodology was performed for two experimental groups, the
first one consisted of 66 control subjects and 20 patients diagnosed with mild AD, the
distribution of data by gender is shown in Table 2-2
Table 2-2: Subjects distribution by gender.
mild AD NC Total
Women 13 48 61
Men 7 18 25
Total 20 66 86
The second one was the whole group described in 2.2.1.
Classification with the first group aims to distinguish between two separated classes, when
including the subjects with CDR = 0.5 we have 3 classes or stages of the diseases that are
not easily separable, to distinguish between these classes we divided the task in two steps as
shown in Figure 2-6:
• Step I: in this step, all the subjects are taken and classified as NC or AD, the AD
class includes patients with mild and very mild AD, this first step can be viewed as a
diagnosis step.
• Step II: in this step we only included the patients diagnosed with probable AD (mild
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or very mild) and performed the validation scheme to classify them as mild AD or very
mild AD, this second step can be viewed as the grading the disease process.
CDR = 0
Normal Control
CDR = 1
mild AD
CDR = 0.5
very mild AD
Step II: vmAD Vs. mAD
Step I: NC Vs. AD
Figure 2-6: Two steps classification
To account for the morphometric variability between genders, we repeated the validation
scheme separately by gender. Cross validation was also done using leave-one-out.
3 Results
For each iteration of the validation procedure, the SVM classifier returns a value that is
often interpreted as the probability of the test subject belonging to the positive class. With
the values collected from the whole experimental group, a receiver operating characteristic
(ROC) curve was constructed since this is the metrics more used in case of binary classi-
fication problems. The area under the curve (AUC), a global measure of the classification
performance, and the equal error rate (EER), the rate for which both false positive rate (type
I error) and false rejection rate (type II error) are equal, were calculated. The EER value
means that there is a decision threshold in which it is possible to achieve simultaneously
sensibility and specificity rates of 1− EER.
3.1 First Group: NC and mild AD
The first experimental group is described in Table 2-2, it has two different classes: Normal
Controls and patients diagnosed with mild Alzheimer’s Disease (the positive class). The fea-
tures for the SVM were calculated using the two similarity measures described in subsection
2.1.4.
Firstly, the complete validation scheme was performed in the whole group, and then we
repeated the process but splitting the group by gender.
3.1.1 With Kullback-Leibler Divergence
In the experiments in which this metrics was used, histograms were divided into 256 bins.
At each iteration of the validation process for this set of experiments, the SVM was trained
with a polynomial kernel. Figure 3-1 and Figure 3-2 show the obtained ROC curves when
using the whole group and when splitting the group by gender, respectively.
The curve in Figure 3-1 has an AUC of 0.96 and an EER of 0.10 these figures demonstrate
the good performance of the classifier even when our experimental group is relatively small
and has an important imbalance of classes, likewise the aging distribution is quite hetero-
geneous in the two classes. The fact that the experiment has shown so clear differences
between the two classes suggests that definitely there are morphological patterns differently
distributed in the two groups.
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Figure 3-1: ROC curve from the classification between mild AD and NC using the KL-
Divergence as the similarity measure
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Figure 3-2: ROC curve from the classification between mild AD and NC using the KL-
Divergence as the similarity measure, separately by gender.
When the experimental group is divided by gender, the classification performance improves
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for women, as shown in Figure 3-2 where the pink curve is closer to the top-left corner,
this curve has an AUC of 0.97 and an EER of 0.08. On the contrary, the classification
performance for men decreases, with an AUC of 0.79 and an EER of 0.29. This suggests
that the patterns that might discriminate between AD and NC are more outstanding in
women than in men. However, the decrease in the performance for men may be due to the
low total number of cases (7 AD and 18 NC).
3.1.2 With Earth Mover’s Distance
The histograms that were compared using EMD have only 64 bins. The SVM kernel used
in this set of experiments is linear, i.e. a first degree polynomial kernel, meaning that the
separation in the feature space is given by a simple hyperplane. The obtained ROC curves
when using the whole group and when splitting the group by gender are shown in Figure
3-3 and Figure 3-4 respectively.
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Figure 3-3: ROC curve for the classification between mild AD and NC using the EMD as
the similarity measure
The curve in Figure 3-3 has an AUC of 0.97 and an EER of 0.11, similar to the curve in Fig-
ure 3-1, this shows that using the EMD reduces the dimensionality of the characterization
of RoI without affecting the classification performance, which is an aside benefit in terms of
the computation. It is noticeable that there is a point in this ROC curve where it is possible
to achieve a sensitivity of 100% with a specificity of 90%.
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Figure 3-4: ROC curve for the classification between mild AD and NC using the EMD as
the similarity measure, separately by gender.
When splitting the group by gender, the classification performance for both women and men
decreases as shown in Figure 3-4, the ROC curve for women shows an AUC of 0.89 and
an EER of 0.21 while the ROC curve for men has an AUC of 0.66 and an EER of 0.43,
as illusrated in Figure 3-2 the classification performance for men is worst than for women,
this observation reinforces the idea that the NC and mild AD patterns differ more in women
than in men.
The Area Under the Curve and the Equal Error Rate of these ROC curves for both sets of
experiments are shown in Table 3-1.
Table 3-1: Classification performance for both sets of experiments. The sensitivity and
sensibility of them is given by 1− EER.
All Women Men
EER AUC EER AUC EER AUC
Using KL-Div 0.10 0.96 0.08 0.97 0.29 0.79
Using EMD 0.11 0.97 0.21 0.89 0.43 0.66
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3.2 Second Group: NC, very mild AD and mild AD
The second group is the same described in Table 2-1 and is composed of three classes:
Normal Controls, patients diagnosed with mild Alzheimer’s Disease and an intermediate
group, composed of patients diagnosed with very mild AD, which is the Mild Cognitive
Impairment. With this group, the experiments were also conducted using both similarity
measures, the KL-Divergence and the EMD.
As described in Section 2.3, the experimentation with this group consists of two binary
classification tasks:
1. AD Detection: This step distinguishes between normal controls and patients with AD
(mild or very mild).
2. Grading the Stage: This phase discriminates between mild and very mild AD.
All the experiments were carried out by separating the group by gender.
3.2.1 With Kullback-Leibler Divergence
In this set of experiments, the histograms were compared using KL divergence, having also
256 bins and the SVM was trained with a polynomial kernel. The obtained ROC curves for
steps 1 and 2 are shown in Figure 3-5 and Figure 3-6 respectively.
The AD detection is a more difficult task when the subjects with very mild AD are included
in the experimental group, Figure 3-5 shows the ROC curves corresponding to this classi-
fication task when the KL-Divergence is used as a similarity measure between RoIs. The
classification performance is very similar for both genders, the ROC curve for women shows
an AUC of 0.82 and an EER of 0.27, while the ROC curve for men has an AUC of 0.81
and an EER of 0.21, suggesting that the descriptive patterns start to get blurred in case of
the women group, while remains almost the same, or even better, for men. This could be
attributed to the inclusion of more men with AD in the new experimental group.
The task of distinguish between stages of the disease is much more difficult than the afore-
mentioned, Figure 3-6 shows that the classification performance for men, in terms of the
EER, is slightly better than for women, the ROC curve for women has an AUC of 0.73 and
an EER of 0.36 while the ROC curve for men shows an AUC of 0.71 and an EER of 0.32.
3.2.2 With Earth Mover’s Distance
When using the EMD, the histograms are composed of 64 bins and the SVM was trained
with a linear kernel. The obtained ROC curves for steps 1 and 2 are shown in Figure 3-7
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Figure 3-5: ROC curve from the classification between AD and NC using the KL-Divergence
as the similarity measure, separately by gender.
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Figure 3-6: ROC curve from the classification between very mild AD and mild AD using
the KL-Divergence as the similarity measure, separately by gender.
and Figure 3-8 respectively.
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Figure 3-7: ROC curve from the classification between AD and NC using the EMD as the
similarity measure, separately by gender.
The Figure 3-7 illustrates the results for the AD detection step when using the EMD as
the distance between RoI, these results are similar to the results obtained using the KL-
Divergence (in Figure 3-5), here we obtained an AUC of 0.82 and an EER of 0.25 for
women, and an AUC of 0.78 and an EER of 0.24 for men. The fact that the classification
performance is similar when using both measures suggests that the morphological patterns
that we found can help to detect AD at early stages and can be captured independently of
the dimensionality of the characterization or the similarity measure.
When trying to discriminate between very mild and mild AD using the EMD as the metric
between RoIs, the classification performance is also better for men than women, as observed
in Figure 3-8 where the blue curve is closer to the top-left corner than the pink. From
these curves we obtained an AUC of 0.72 and an EER of 0.36, for women, and an AUC of
0.78 and an EER of 0.27, for men. It is a remarkable fact that, when using both similarity
measures, the classification performance between stages of the disease is better for men than
for women. In contrast, the classification performance between NC and mild AD is better
for women than for men, as shown in Section 3.1.
Table 3-2 summarizes the classification performance, in terms of the AUC and the EER, for
all the experiments with the second experimental group.
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Figure 3-8: ROC curve from the classification between very mild AD and mild AD using
the EMD as the similarity measure, separately by gender.
Table 3-2: Classification performance for the experiments with the second group. The sen-
sitivity and sensibility are given by 1− EER.
Step 1: Step 2:
NC Vs. AD vmAD Vs. mAD
Women Men Women Men
EER AUC EER AUC EER AUC EER AUC
Using KL-Div 0.27 0.82 0.28 0.81 0.36 0.73 0.32 0.71
Using EMD 0.25 0.82 0.24 0.78 0.36 0.72 0.27 0.78
4 Discussion
In this work we have presented an automatic strategy to learn brain models for different
groups based on morphological features by applying a novel fusion strategy, from these mod-
els we obtain discerning regions and then these regions may be used to extract descriptive
signatures of the morphological information which it is present in normal and pathological
brains. Furthermore, we have shown how it is possible to obtain useful classification features
by using two different similarity measures to compare RoI in a test MRI against RoI in the
brain models.
By applying the proposed strategy the classification results are an improvement with respect
to previous results that use the same group as our first experimental group and the same
validation scheme. As shown in Section 3.1, with this group we obtained Equal Error Rates
of 0.10 and 0.11 using the KL-Divergence and EMD respectively while Toews et al. [33] and
Rueda et al. [52] obtained EER of 0.20 and 0.14 respectively.
The EER that we obtained means that we can achieve about 90% of sensitivity and specificity
at the same time when detecting mild AD. The same task was carried out by Cuignet et al.
[24] using the ADNI database, but assessing 10 different methods and reporting that the best
method achieved around 80% of sensitivity and 95% of specificity. Similar or slightly lower
results where found using methods based or relying on segmentation of the brain main tissues,
namely cerebrospinal fluid, gray and white matters [26, 34, 35, 36, 37]. Other methods with
similar classificaion performances use elastic registration [53], semi-automatic segmentation
of the hippocampus [38], or combine measures over the mentioned features [39, 40, 19, 41, 42].
Additionally, when comparing control with mild AD, the experimental groups was assessed
by separating by gender since there exist well documented brain anatomical differences be-
tween them that might bias the model [54]. When using both metrics, the classification
results for women outperform what was observed in the men case, this may be due to the
low number of men cases (7 AD and 18 NC), likely a consequence of the fact that women
are at a greater risk for developing Alzheimer’s disease [55].
When including patients with very mild AD we obtain Equal Error Rates, 0.25 for women
and 0.24 for men (see Table 3-2). This means that we can achieve about 75% of sensitivity
and specificity at the same time when detecting AD in women and 76% of sensitivity and
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specificity when detecting AD in men. Toews et al. [33] and Rueda et al. [52] also used this
experimental group to classify AD, obtaining EER of 0.29 and 0.24 respectively. Althought
they used the same experimental group, they performed a leave-one-out validatio scheme
with the whole group while we have performed a leave-one-out validation scheme separately
by gender.
4.1 Products
While developing this thesis, three works were presented in international conferences:
• “Estudio del Tamao del Campo de Anlisis en la Tarea de Clasificacin de IRM en
Cerebros con la Enfermedad de Alzheimer” in VIII International Seminar on Medical
Image Processing and Analysis - SIPAIM (2012). [56]
• “An Automatic MRI Fusion Strategy Based on Nonnegative Matrix Factorization” in
IX International Seminar on Medical Image Processing and Analysis - SIPAIM (2013).
[57]
• “Morphometry-Based Comparison of Relevant Brain Regions for Alzheimer’s Disease
Detection” in X International Seminar on Medical Image Processing and Analysis -
SIPAIM (2014). [58]
4.2 Future Work
Future work includes integrating prior knowledge to improve the models of the brains, this
knowledge could include other neuropsychological tests and demographic data, extensive
experimentation in larger databases as the Alzheimer’s Disease Neuroimaging Initiative
(http://adni.loni.usc.edu/), analizing the functional relations between the obtained re-
gions of interest and exploiting the used metrics to explore and compare intermediate stages
of the disease.
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